Skip the wait and schedule your appointments online or through MyChart.

RSV (Respiratory Syncytial Virus) season: What parents need to know

Research & Innovation

Ovarian Clinical Trials

Clinical Trials

Gradalis CL-PTL-135

Physician & Study Coordinator

Study Coordinator

Janine Schippang
484-658-1790

JanineL.Schippang@sluhn.org

Close

Synopsis

Synopsis: Blood and Tissue Procurement Protocol for Product Development and Research

Close

Eligibility Criteria
  • Solid tumors including but not limited to ovarian cancer, including solid lesions and/or liquid tumor sites (i.e., asictes, pleual fluid)
  • Patients must agree to collection of blood and/or tumor tissue/fluid that is obtained during a standard of care procedure or visit

Close

Amgen 20170770

Physician & Study Coordinator

Physician

Asim Ali, MD

Asim Ali, MD

Study Coordinator

Janine Schippang
484-658-1790

JanineL.Schippang@sluhn.org

Close

Synopsis

Synopsis: A Phase 3 Radomized Placebo Controlled Double Blind Study of Romiplostim forthe treatment of Chemotherapy- induced Thrombocytopenia in Patients receiving chemotherapy for treatment Non-small cell lung cancer (NSCLC), Ovarian Cancer, or Breast cancer

Close

Eligibility Criteria
  • Is ≥18 years of age, at the time of signing the informed consent
  • Stage I, II, III, or IV locally advanced NSCLC, Breast cancer, or ovarian cancer or any stagerecurrent disease.
  • Patients must have platelet count less than 85 x 10^9/L on day 1 of the study
  • Patients must be receiving cancer treatment wih 21 – or 28- day cycles using one of thefollowing carboplatin- based combination chemotherapy regimens: carboplatin/gemcitabine based, carboplatin/ premextred based, carboplatin/ liposomal doxorubicinbased, or carboplatin/ taxane based (which includes either paclitaxel, nab- paclitaxel, ordocetaxel)
  • Patients must have at least 3 remaining planned cycles of chemotherapy at studyenrollment
  • No previous use of romiplostim, pegylated recombinant human megakaryocyte growth anddevelopment factor, eltromobag, recombinant human TPO, any other TPO receptorantagonist, or any investigational platelet producing agent

Close